tert-butyl-3-[(phenylamino)methyl]azetidine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: tert-butyl-3-[(phenylamino)methyl]azetidine-1-carboxylate
• 英文别名: tert-butyl 3-(anilinomethyl)azetidine-1-carboxylate；N-(1-Boc-Azetidine-3-ylmethyl)aniline
• 化学式: C₁₅H₂₂N₂O₂
• 分子量: 262.352
• InChiKey: NPIXZBXNUOUCQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl-3-[(phenylamino)methyl]azetidine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 N-(azetidin-3-ylmethyl)aniline
  参考文献：
  名称：

  [EN] BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION
  [FR] COMPOSÉS DE BENZAZÉPINE DICARBOXAMIDE À FONCTION AMIDE TERTIAIRE

  摘要：

  这项发明涉及新的苯并氮杂环二羧酰胺化合物，其化学式为（I），其中R1至R3如描述和权利要求中所定义，并且其药学上可接受的盐。这些化合物是TLR激动剂，因此可能用作治疗癌症、自身免疫疾病、炎症、败血症、过敏、哮喘、移植排斥、移植物抗宿主病、免疫缺陷和传染病等疾病的药物。

  公开号：

  WO2017202704A1
• 作为产物：
  描述：

  溴苯 、 1-Boc-3-氨甲基氮杂环丁烷 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 甲苯 为溶剂， 反应 13.5h， 以Ca. 83 mg的产率得到tert-butyl-3-[(phenylamino)methyl]azetidine-1-carboxylate
  参考文献：
  名称：

  [EN] BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION
  [FR] COMPOSÉS DE BENZAZÉPINE DICARBOXAMIDE À FONCTION AMIDE TERTIAIRE

  摘要：

  这项发明涉及新的苯并氮杂环二羧酰胺化合物，其化学式为（I），其中R1至R3如描述和权利要求中所定义，并且其药学上可接受的盐。这些化合物是TLR激动剂，因此可能用作治疗癌症、自身免疫疾病、炎症、败血症、过敏、哮喘、移植排斥、移植物抗宿主病、免疫缺陷和传染病等疾病的药物。

  公开号：

  WO2017202704A1

文献信息

• Heterocyclic analgesic compounds and methods of use thereof
  申请人：——

  公开号：US20020016337A1

  公开（公告）日：2002-02-07

  One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

  本发明的一个方面涉及新颖的杂环化合物。本发明的第二个方面涉及将这些新颖的杂环化合物作为各种细胞受体的配体，包括阿片受体、其他G蛋白偶联受体和离子通道。本发明的另一个方面涉及将这些新颖的杂环化合物用作镇痛剂。
• 3-아미노메틸 아제티딘 화합물, 이를 포함하는 우울증, 정신 질환, 조루증, 또는 신경병증성 통증의 예방 또는 치료용 약학 조성물, 및 상기 약학 조성물을 포함하는 제제
  申请人：KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY 한국과학기술연구원(319980077518) BRN ▼209-82-03522

  公开号：KR101561992B1

  公开（公告）日：2015-10-20

  본 발명은 특정 신경 전달 물질들의 재흡수를 높은 효율로 방지하여 우울증, 정신 질환, 조루증, 또는 신경병증성 통증의 치료제 또는 예방제로 사용될 수 있는 신규한 3-아미노메틸 아제티딘 화합물, 세레토닌 및 도파민 또는 노에피네프린의 재흡수를 억제할 수 있고 우울증, 정신 질환, 조루증, 또는 신경병증성 통증에 대하여 높은 치료 효과 또는 예방 효과를 갖는 약학 조성물과, 상기 약학 조성물을 포함하는 제제에 관한 것이다.

  本发明涉及一种新型的3-氨基甲基-异赛替啶化合物，可高效地防止特定神经传递物质的再吸收，可用作抑郁症、精神障碍、勃起功能障碍或神经病理性疼痛的治疗剂或预防剂，可抑制血清素、多巴胺或去甲肾上腺素的再吸收，并具有对抑郁症、精神障碍、勃起功能障碍或神经病理性疼痛具有高治疗或预防效果的药学组合物，以及涉及包含上述药学组合物的制剂。
• Benzazepine dicarboxamide compounds with tertiary amide function
  申请人：Hoffmann-La Roche Inc.

  公开号：US10370338B2

  公开（公告）日：2019-08-06

  This invention relates to new benzazepine dicarboxamide compounds of the formula wherein R1 to R3 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.

  本发明涉及新的苯并氮杂卓二甲酰胺化合物，其式为 其中 R1 至 R3 如说明书和权利要求书中所定义，以及其药学上可接受的盐类。这些化合物是 TLR 激动剂，因此可用作治疗癌症、自身免疫性疾病、炎症、败血症、过敏、哮喘、移植物排斥、移植物抗宿主疾病、免疫缺陷和传染性疾病等疾病的药物。
• Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine
  作者：Minsoo Han、Chiman Song、Nakcheol Jeong、Hoh-Gyu Hahn

  DOI：10.1021/ml500187a

  日期：2014.9.11

  For a development of broad spectrum antidepressant 3-aminoazetidine derivatives, two series of compounds were explored by bioisosteric modification of 3-α-oxyazetidine. We synthesized 166 novel 3-aminoazetidine derivatives in series A and B, starting from Boc-protected 3-azetidinone (3) and Boc-protected 3-azetidinal (9) respectively, through parallel syntheses. The inhibitory reuptake activities against serotonin (5-HT), norepinephrine (NE), and dopamine (DA) neurotransmitters were measured by the Neurotransmitter Transporter Uptake Assay Kit using the human embryonic kidney 293 (HEK293) cells stably transfected with the respective three kinds of human transporters (hSERT, hNET, and hDAT). Our study aimed to identify compounds having relative inhibitory activities against hSERT > hNET > hDAT. Lead optimization including microsomal stability, CYP, hERG assay, Ames test, BBB, and PK study resulted in the identification of compound 10dl as a candidate for further studies.
• BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3464245B1

  公开（公告）日：2020-10-14